BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Satake K, Takeuchi T. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 1994;9:720-4. [PMID: 7846015 DOI: 10.1097/00006676-199411000-00008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Liu F, Zhang Y, Men T, Jiang X, Yang C, Li H, Wei X, Yan D, Feng G, Yang J, Bergquist J, Wang B, Jiang W, Mi J, Tian G. Quantitative proteomic analysis of gastric cancer tissue reveals novel proteins in platelet-derived growth factor b signaling pathway. Oncotarget 2017;8:22059-75. [PMID: 28423550 DOI: 10.18632/oncotarget.15908] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
2 Teich N, Kleeff J, Lochs H, Mössner J, Keim V, Friess H, Ockenga J. The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterol 2005;5:20. [PMID: 15969757 DOI: 10.1186/1471-230X-5-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics. 2012;75:3081-3097. [PMID: 22498886 DOI: 10.1016/j.jprot.2012.03.046] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
4 Wenig BM, Albores-Saavedra J, Buetow PC, Heffess CS. Pancreatic mucinous cystic neoplasm with sarcomatous stroma: a report of three cases. Am J Surg Pathol 1997;21:70-80. [PMID: 8990143 DOI: 10.1097/00000478-199701000-00008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 2.2] [Reference Citation Analysis]
5 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. WJG 2021;27:5851-89. [DOI: 10.3748/wjg.v27.i35.5851] [Reference Citation Analysis]
6 Haycox, Lombard, Neoptolemos, Walley. Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer: REVIEW: DETECTION AND DIAGNOSIS OF PANCREATIC CANCER. Alimentary Pharmacology & Therapeutics 1998;12:937-48. [DOI: 10.1046/j.1365-2036.1998.00393.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
7 Maire F, Micard S, Hammel P, Voitot H, Lévy P, Cugnenc PH, Ruszniewski P, Puig PL. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 2002;87:551-4. [PMID: 12189555 DOI: 10.1038/sj.bjc.6600475] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 4.8] [Reference Citation Analysis]
8 Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas. 2007;34:318-324. [PMID: 17414054 DOI: 10.1097/mpa.0b013e31802ee9c7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
9 Zyromski NJ, Haidenberg J, Sarr MG. Necrotizing Pancreatitis Caused by Pancreatic Ductal Adenocarcinoma: . Pancreas 2001;22:431-2. [DOI: 10.1097/00006676-200105000-00015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Daamen LA, Groot VP, Heerkens HD, Intven MP, van Santvoort HC, Molenaar IQ. Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer. HPB 2018;20:297-304. [DOI: 10.1016/j.hpb.2017.11.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
11 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
12 O'Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol 2021;27:4045-87. [PMID: 34326612 DOI: 10.3748/wjg.v27.i26.4045] [Reference Citation Analysis]
13 Kau SY, Shyr YM, Su CH, Wu CW, Lui WY. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg. 1999;188:415-420. [PMID: 10195726 DOI: 10.1016/s1072-7515(98)00326-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
14 Nakao A, Oshima K, Nomoto S, Takeda S, Kaneko T, Ichihara T, Kurokawa T, Nonami T, Takagi H. Clinical usefulness of CA-19-9 in pancreatic carcinoma. Semin Surg Oncol 1998;15:15-22. [PMID: 9671952 DOI: 10.1002/(sici)1098-2388(199807/08)15:1<15::aid-ssu4>3.0.co;2-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
15 Zhang Y, Qiu L, Wang Y, Qin X, Li Z. High-throughput and high-sensitivity quantitative analysis of serum unsaturated fatty acids by chip-based nanoelectrospray ionization-Fourier transform ion cyclotron resonance mass spectrometry: early stage diagnostic biomarkers of pancreatic cancer. Analyst 2014;139:1697-706. [PMID: 24551873 DOI: 10.1039/c3an02130k] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
16 Liu D, Cao L, Yu J, Que R, Jiang W, Zhou Y, Zhu L. Diagnosis of pancreatic adenocarcinoma using protein chip technology. Pancreatology 2009;9:127-35. [PMID: 19077463 DOI: 10.1159/000178883] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
17 Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bombardieri E, Geraghty JG. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol 1996;5:49-63. [PMID: 8853239 DOI: 10.1016/s0960-7404(96)80001-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
18 Chu TM. Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 1997;11:225-31. [PMID: 9219065 DOI: 10.1002/(sici)1098-2825(1997)11:4<225::aid-jcla9>3.0.co;2-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Rückert F, Pilarsky C, Grützmann R. Serum tumor markers in pancreatic cancer-recent discoveries. Cancers (Basel) 2010;2:1107-24. [PMID: 24281109 DOI: 10.3390/cancers2021107] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
20 Tang Y, Cui Y, Zhang S, Zhang L. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. Prog Mol Biol Transl Sci 2019;162:121-40. [PMID: 30905445 DOI: 10.1016/bs.pmbts.2019.01.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
21 Frena A. SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker. Int J Biol Markers 2001;16:189-97. [DOI: 10.1177/172460080101600306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270. [PMID: 17097848 DOI: 10.1016/j.ejso.2006.10.004] [Cited by in Crossref: 467] [Cited by in F6Publishing: 408] [Article Influence: 31.1] [Reference Citation Analysis]
23 Ciprani D, Morales-Oyarvide V, Qadan M, Hank T, Weniger M, Harrison JM, Rodrigues C, Horick NK, Mino-Kenudson M, Ferrone CR, Warshaw AL, Lillemoe KD, Fernández-Del Castillo C. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology 2020;20:729-35. [PMID: 32332003 DOI: 10.1016/j.pan.2020.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
24 Xing H, Wang J, Wang Y, Tong M, Hu H, Huang C, Li D. Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis. Gastroenterol Res Pract. 2018;2018:8704751. [PMID: 30584422 DOI: 10.1155/2018/8704751] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
25 Castellanos JA, Merchant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol 2014;21:747-51. [PMID: 24092447 DOI: 10.1245/s10434-013-3289-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
26 Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 2009;38:422-6. [PMID: 19214136 DOI: 10.1097/MPA.0b013e318198281d] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
27 Mendieta Zerón H, García Flores JR, Romero Prieto ML. Limitations in improving detection of pancreatic adenocarcinoma. Future Oncol. 2009;5:657-668. [PMID: 19519205 DOI: 10.2217/fon.09.32] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
28 Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, Srivastava S, Frazier ML, Sen S, Hollingsworth MA, Rinaudo JA, Killary AM, Brand RE. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS One 2015;10:e0139049. [PMID: 26431551 DOI: 10.1371/journal.pone.0139049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
29 Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW, Friess H. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007;34:205-214. [PMID: 17312459 DOI: 10.1097/01.mpa.0000250128.57026.b2] [Cited by in Crossref: 110] [Cited by in F6Publishing: 94] [Article Influence: 7.9] [Reference Citation Analysis]
30 Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia. 2004;6:674-686. [PMID: 15548376 DOI: 10.1593/neo.04262] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
31 Parikh AA, Lowy AM. Pancreatic cancer: Can we screen? How should we stage? Curr Gastroenterol Rep 1999;1:166-74. [DOI: 10.1007/s11894-996-0017-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
32 Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, Ensink E, Bern M, Hostetter G, Hartman D, Huang Y, Brand RE, Haab BB. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A. Mol Cell Proteomics. 2015;14:1323-1333. [PMID: 25733690 DOI: 10.1074/mcp.m114.047837] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
33 Zhang K, Hua YQ, Wang D, Chen LY, Wu CJ, Chen Z, Liu LM, Chen H. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med 2019;17:30. [PMID: 30658662 DOI: 10.1186/s12967-019-1782-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
34 Furukawa H, Okada S, Saisho H, Ariyama J, Karasawa E, Nakaizumi A, Nakazawa S, Murakami K, Kakizoe T. Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 1996;78:986-90. [PMID: 8780535 DOI: 10.1002/(SICI)1097-0142(19960901)78:5<986::AID-CNCR7>3.0.CO;2-A] [Cited by in Crossref: 73] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
35 Lévy P. Adénocarcinome du pancréas : le dosage du CA 19-9 a-t-il un intérêt ? La Presse Médicale 2008;37:88-94. [DOI: 10.1016/j.lpm.2007.05.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]